Online inquiry

IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1121MR)

This product GTTS-WQ1121MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1121MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ524MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ11885MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ5517MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ10421MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ5187MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ9221MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ12603MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ5446MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW